Table 2 Patient characteristics of IDH wild-type LGG.
Group A | Group B | ||
|---|---|---|---|
(N = 41) | (N = 50) | P value | |
Clinical characteristics | |||
Sex—no. (%) | |||
Male | 26 (63.4%) | 32 (64.0%) | 0.954a |
Female | 15 (36.6%) | 18 (36.0%) | |
Age—year (SD) | 44.2 ± 12.0 | 46.1 ± 13.6 | 0.273b |
Survival—months (SD) | 26.2 ± 13.8 | 23.4 ± 13.7 | 0.962b |
Imaging characteristics | |||
Tumor location—no. (%) | (N = 41) | (N = 50) | 0.14a |
Frontal | 27 (65.9%) | 28 (56.0%) | |
Parietal | 2 (4.9%) | 11 (22.0%) | |
Temporal | 9 (11%) | 8 (16.0%) | |
Others | 3 (7.3%) | 3 (6.0%) | |
Histopathological diagnosis—no. (%) | (N = 40) | (N = 50) | 1.000a |
Astrocytoma | 32 (80.0%) | 40 (80%) | |
Oligodendroglioma | 8 (20.0%) | 10 (20%) | |
WHO grading—no. (%) | (N = 39) | (N = 50) | 0.926a |
II | 23 (59.0%) | 29 (58.0%) | |
III | 16 (41.0%) | 21 (42.0%) | |
TERT status—no. (%) | (N = 39) | (N = 45) | 0.579a |
Mutation | 15 (38.5%) | 20 (44.4%) | |
Wild type | 24 (61.5%) | 25 (55.6%) | |
1p19q status—no. (%) | (N = 40) | (N = 48) | 0.338a |
Codeletion | 9 (22.5%) | 7 (14.6%) | |
Retain | 31 (77.5%) | 41 (85.4%) | |
